How MSI and TMB Factor into Current Biomarker Testing Panels

Videos - Video, ASCO
Sanjiv Agarwala, MD
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Related Items
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 13, 2020 in Interview with the Innovators, Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on November 2, 2020 in Interview with the Innovators, Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 11, 2020 in Interview with the Innovators, Video
Combination Therapy as Maintenance in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 6, 2020 in Interview with the Innovators, Video
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 15, 2020 in Interview with the Innovators, Video
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 8, 2020 in Interview with the Innovators, Video
Choosing Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 18, 2020 in Interview with the Innovators, Video
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 11, 2020 in Interview with the Innovators, Video
Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN
Videos published on July 28, 2020 in Interview with the Innovators, Video
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on July 14, 2020 in Interview with the Innovators, Video
Last modified: April 27, 2020